MUMBAI -(Dow Jones)- Aurobindo Pharma Ltd. (524804.BY) said Friday it has received the U.S Food and Drug Administration's final approval for selling a generic version of the epilepsy drug, lamotrigine.
The approval is for 5-milligram and 25-mg tablets, the Hyderabad, India-based pharmaceutical company said in a statement to the Bombay Stock Exchange.
The drug is a generic form of GlaxoSmithKline PLC's (GSK) Lamictal tablets.
The company said it will launch the product soon.
-By Gurdev Singh Virk; Dow Jones Newswires; 91 22 6145 6119; Gurdev.Singh@dowjones.com